Revenue From Sales Of Self-Manufactured Tcmd Products was Universe Pharmaceuticals’s largest product and service line in fiscal 2025, bringing in $13.26B of $17.86B (74%).
| Product and Service | FY 2025 |
|---|---|
| Revenue From Sales Of Self-Manufactured Tcmd Products | $13.26B |
| Revenue From Sales Of Third-Party Products | $4.60B |
| Total | $17.86B |
Universe Pharmaceuticals brought in $17.86B from its two product and service lines in fiscal 2025, the year ended September 30, 2025. Revenue From Sales Of Self-Manufactured Tcmd Products was the largest at $13.26B (74.3%), ahead of Revenue From Sales Of Third-Party Products at $4.60B (25.7%).
Universe Pharmaceuticals (UPC) reports its revenue by product and service. In fiscal 2025, Revenue From Sales Of Self-Manufactured Tcmd Products was its largest product and service line, bringing in $13.26B (74.3% of the total), followed by Revenue From Sales Of Third-Party Products at $4.60B (25.7%).
Revenue From Sales Of Self-Manufactured Tcmd Products was Universe Pharmaceuticals' largest product and service line in fiscal 2025, bringing in $13.26B, or 74.3% of the $17.86B total across its two product and service lines.
Every figure comes from Universe Pharmaceuticals' annual financial filings, as reported. Each line keeps the name Universe Pharmaceuticals gives it, and years follow its fiscal calendar.
Universe Pharmaceuticals' revenue by product and service goes back to fiscal 2025, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.